NervGen Pharma Corp. (NGEN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NervGen Pharma Corp. (NGEN) has a cash flow conversion efficiency ratio of -1.505x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.34 Million) by net assets ($5.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NervGen Pharma Corp. balance sheet quality to measure how much of total assets are equity-financed.
NervGen Pharma Corp. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how NervGen Pharma Corp.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore NGEN long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
NervGen Pharma Corp. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NervGen Pharma Corp. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gipta Ofis Kirtasiye ve Promosyon Ãrünleri Imalat Sanayi A.S.
IS:GIPTA
|
-0.172x |
|
Ha Tien 1 Cement JSC
VN:HT1
|
0.062x |
|
Mayer Steel Pipe Corp
TW:2020
|
0.117x |
|
Astral Resources NL
AU:AAR
|
-0.011x |
|
Sierra Metals Inc.
TO:SMT
|
0.249x |
|
PULSION Medical Systems SE
MU:PUS
|
0.160x |
|
Honma Golf Limited
F:HF5
|
0.008x |
|
Sinphar Pharmaceutical Co Ltd
TW:1734
|
0.031x |
Annual Cash Flow Conversion Efficiency for NervGen Pharma Corp. (2018–2025)
The table below shows the annual cash flow conversion efficiency of NervGen Pharma Corp. from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see NervGen Pharma Corp. (NGEN) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.48 Million | $-19.50 Million | -5.608x | +14.20% |
| 2024-12-31 | $2.57 Million | $-16.83 Million | -6.536x | -216.26% |
| 2023-12-31 | $-2.01 Million | $-11.30 Million | 5.622x | +525.55% |
| 2022-12-31 | $13.34 Million | $-17.63 Million | -1.321x | -168.70% |
| 2021-12-31 | $16.95 Million | $-8.33 Million | -0.492x | +53.85% |
| 2020-12-31 | $5.93 Million | $-6.32 Million | -1.065x | +23.12% |
| 2019-12-31 | $6.00 Million | $-8.31 Million | -1.386x | -234.95% |
| 2018-12-31 | $2.51 Million | $-1.04 Million | -0.414x | -- |
About NervGen Pharma Corp.
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's… Read more